Stem cell treatment for severe neuromyelitis optica relapse
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new stem cell treatment for people with a severe relapse of neuromyelitis optica (NMO), a rare autoimmune disease that affects the eyes and spinal cord. The treatment may help reduce damage and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 65 years old.
- You have a blood relative (like a sibling or parent) who is between 19 and 70 and can donate bone marrow.
- You have been diagnosed with AQP4 antibody-positive NMO.
- You have had a severe relapse within the last 28 days, affecting either your spinal cord (with a disability score of 4.0–8.5) or your vision (with vision of 20/200 or worse in at least one eye).
- You are willing to use birth control (if you could become pregnant or father a child) for 12 months after treatment.
- You have no major heart problems, recent cancer, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This trial tests a new cell-based treatment (called HY001N) for people with certain autoimmune neurological diseases that have not responded to standard treatments. The treatment aims to reset the immune system to reduce attacks and improve symptoms.
This study tests a drug called sivelestat for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a relapse. The drug may help reduce damage during the relapse and improve recovery.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Hear when a new Neuromyelitis Optica Spectrum Disorder Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.